UroGen Pharma Ltd. — Institutional Ownership
Which tracked institutions hold URGN, and how they changed the position last quarter. Latest holdings as of Jun 30, 2026. Source: SEC 13-F filings.
24
Funds holding
$410128372
Total value held
Buying
23 added/new · 0 reduced
| # | Institution | Value | Shares | Δ Shares | Change (QoQ) |
|---|---|---|---|---|---|
| 1 | Blackrock, Inc. | $117813765 | 3201461 | +355894 | +12.51% |
| 2 | Morgan Stanley | $94810189 | 2576363 | +16325 | +0.64% |
| 3 | Jefferies Financial Group Inc. | $80947194 | 2199652 | +2199652 | NEW BUY |
| 4 | State Street Corp | $36913013 | 1003071 | +128895 | +14.74% |
| 5 | Goldman Sachs Group Inc | $30169892 | 819834 | +221306 | +36.98% |
| 6 | Bank Of America Corp /De/ | $17505834 | 475702 | +348919 | +275.21% |
| 7 | Northern Trust Corp | $11208175 | 304570 | +28632 | +10.38% |
| 8 | Ubs Group Ag | $4469764 | 121461 | +121461 | NEW BUY |
| 9 | Bank Of New York Mellon Corp | $4159416 | 113028 | +14086 | +14.24% |
| 10 | Wells Fargo & Company/Mn | $2952612 | 80234 | +24477 | +43.90% |
| 11 | Truist Financial Corp | $2660125 | 72286 | — | Held |
| 12 | Jpmorgan Chase & Co | $1426352 | 39544 | +18422 | +87.22% |
| 13 | Ameriprise Financial Inc | $1165383 | 31668 | +31668 | NEW BUY |
| 14 | Invesco Ltd. | $954113 | 25927 | +25927 | NEW BUY |
| 15 | Citigroup Inc | $841653 | 22871 | +19469 | +572.28% |
| 16 | Franklin Resources Inc | $708878 | 19263 | +2518 | +15.04% |
| 17 | Royal Bank Of Canada | $407000 | 11060 | +2514 | +29.42% |
| 18 | Barclays Plc | $374439 | 10175 | +540 | +5.60% |
| 19 | Janus Henderson Group Plc | $343132 | 19100 | +19100 | NEW BUY |
| 20 | Prudential Financial Inc | $256680 | 6975 | +6975 | NEW BUY |
| 21 | Federated Hermes, Inc. | $35254 | 958 | +958 | NEW BUY |
| 22 | Us Bancorp \De\ | $2981 | 81 | +81 | NEW BUY |
| 23 | Pnc Financial Services Group, Inc. | $2502 | 68 | +5 | +7.94% |
| 24 | Amalgamated Financial Corp. | $26 | 2960 | +2960 | NEW BUY |
Aggregated across tracked institutional filers. Reported quarterly on SEC Form 13-F and may lag. For research only — not investment advice.